Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

被引：41

作者：

Cai, Hongzhen ^{[1
,2
]}

Li, Man ^{[1
,2
]}

Deng, Ruiyi ^{[1
,2
]}

Wang, Mopei ^{[3
]}

Shi, Yanyan ^{[1
]}

机构：

[1] Peking Univ Third Hosp, Res Ctr Clin Epidemiol, Beijing 100191, Peoples R China

[2] Peking Univ, Hlth Sci Ctr, Beijing 100191, Peoples R China

[3] Peking Univ Third Hosp, Dept Med Oncol & Radiat Sickness, Beijing 100191, Peoples R China

来源：

BIOMARKER RESEARCH | 2022年 / 10卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Gastric cancer; Immunotherapy; Anti-PD-1; Biomarker; Checkpoint inhibitor; GASTROESOPHAGEAL JUNCTION; OPEN-LABEL; T-CELLS; PD-1; BLOCKADE; 22C3; PHARMDX; PHASE-II; EXPRESSION; NIVOLUMAB; EFFICACY; LAG-3;

D O I：

10.1186/s40364-022-00413-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastric cancer is characterized by high morbidity and mortality worldwide. Early-stage gastric cancer is mainly treated with surgery, while for advanced gastric cancer, the current treatment options remain insufficient. In the 2022 NCCN Guidelines for Gastric Cancer, immunotherapy is listed as a first-line option for certain conditions. Immunotherapy for gastric cancer mainly targets the PD-1 molecule and achieves therapeutic effects by activating T cells. In addition, therapeutic strategies targeting other molecules, such as CTLA4, LAG3, Tim3, TIGIT, and OX40, have also been developed to improve the treatment efficacy of gastric cancer immunotherapy. This review summarizes the molecular biomarkers of gastric cancer immunotherapy and their clinical trials.

引用

页数：13

共 101 条

[1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

[2] Gastric Cancer, Version 2.2022 [J].

Ajani, Jaffer A. ;

D'Amico, Thomas A. ;

Bentrem, David J. ;

Chao, Joseph ;

Cooke, David ;

Corvera, Carlos ;

Das, Prajnan ;

Enzinger, Peter C. ;

Enzler, Thomas ;

Fanta, Paul ;

Farjah, Farhood ;

Gerdes, Hans ;

Gibson, Michael K. ;

Hochwald, Steven ;

Hofstetter, Wayne L. ;

Ilson, David H. ;

Keswani, Rajesh N. ;

Kim, Sunnie ;

Kleinberg, Lawrence R. ;

Klempner, Samuel J. ;

Lacy, Jill ;

Ly, Quan P. ;

Matkowskyj, Kristina A. ;

McNamara, Michael ;

Mulcahy, Mary F. ;

Outlaw, Darryl ;

Park, Haeseong ;

Perry, Kyle A. ;

Pimiento, Jose ;

Poultsides, George A. ;

Reznik, Scott ;

Roses, Robert E. ;

Strong, Vivian E. ;

Su, Stacey ;

Wang, Hanlin L. ;

Wiesner, Georgia ;

Willett, Christopher G. ;

Yakoub, Danny ;

Yoon, Harry ;

McMillian, Nicole ;

Pluchino, Lenora A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02) :167-192

[3] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[4] Clinical epidemiology of gastric cancer [J].

Ang, Tiing Leong ;

Fock, Kwong Ming .

SINGAPORE MEDICAL JOURNAL, 2014, 55 (12) :621-628

[5] The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer [J].

Aydin, Elif Merve ;

Demir, Tevriz Dilan ;

Seymen, Nogayhan ;

Said, Sawsan Sudqi ;

Oktem-Okullu, Sinem ;

Tiftikci, Arzu ;

Cicek, Bahattin ;

Tokat, Fatma ;

Tozun, Nurdan ;

Ince, Umit ;

Sezerman, Ugur ;

Sayi-Yazgan, Ayca .

IMMUNOLOGY LETTERS, 2021, 239 :1-11

[6] Mechanisms of the Epithelial-Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer [J].

Baj, Jacek ;

Korona-Glowniak, Izabela ;

Forma, Alicja ;

Maani, Amr ;

Sitarz, Elzbieta ;

Rahnama-Hezavah, Mansur ;

Radzikowska, Elzbieta ;

Portincasa, Piero .

CELLS, 2020, 9 (04)

[7] Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer [J].

Bang, Yung-Jue ;

Cho, Jae Yong ;

Kim, Yeul Hong ;

Kim, Jin Won ;

Di Bartolomeo, Maria ;

Ajani, Jaffer A. ;

Yamaguchi, Kensei ;

Balogh, Agnes ;

Sanchez, Teresa ;

Moehler, Markus .

CLINICAL CANCER RESEARCH, 2017, 23 (19) :5671-5678

[8] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Feyereislova, Andrea ;

Chung, Hyun C. ;

Shen, Lin ;

Sawaki, Akira ;

Lordick, Florian ;

Ohtsu, Atsushi ;

Omuro, Yasushi ;

Satoh, Taroh ;

Aprile, Giuseppe ;

Kulikov, Evgeny ;

Hill, Julie ;

Lehle, Michaela ;

Ruschoff, Josef ;

Kang, Yoon-Koo .

LANCET, 2010, 376 (9742) :687-697

[9] Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab [J].

Boku, Narikazu ;

Satoh, Taroh ;

Ryu, Min-Hee ;

Chao, Yee ;

Kato, Ken ;

Chung, Hyun Cheol ;

Chen, Jen-Shi ;

Muro, Kei ;

Kang, Won Ki ;

Yeh, Kun-Huei ;

Yoshikawa, Takaki ;

Oh, Sang Cheul ;

Bai, Li-Yuan ;

Tamura, Takao ;

Lee, Keun-Wook ;

Hamamoto, Yasuo ;

Kim, Jong Gwang ;

Chin, Keisho ;

Oh, Do-Youn ;

Minashi, Keiko ;

Cho, Jae Yong ;

Tsuda, Masahiro ;

Nishiyama, Taihei ;

Chen, Li-Tzong ;

Kang, Yoon-Koo .

GASTRIC CANCER, 2021, 24 (04) :946-958

[10] A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY - CTLA-4 [J].

BRUNET, JF ;

DENIZOT, F ;

LUCIANI, MF ;

ROUXDOSSETO, M ;

SUZAN, M ;

MATTEI, MG ;

GOLSTEIN, P .

NATURE, 1987, 328 (6127) :267-270

← 1 2 3 4 5 6 7 8 9 10 →